Table of Contents Author Guidelines Submit a Manuscript

Extranodal Lymphomas

Call for Papers

Lymphomas have attracted the interest of a large spectrum of scientists in biology and medicine in general since 19th century. Epidemiology, histopathology, systematic studies, and molecular biology have made an enormous progress during the last decades. Lymphoma classification, under an endless revision, remains a rather historical event in systemic biology. Therapeutic efforts employing radiotherapy and alkylating agents have dramatically changed prognosis. On the other hand, the clinician’s current armament is now expanded from radiotherapy and chemotherapy to immunology-based modes of treatment employing both immune-acting molecules like monoclonals but also cellular therapies as well, including stem cell transplantation and more recently bio-engineered cells like the chimeric antigen receptors (CAR) T cells. Among the problems faced in the management of lymphomas, those affecting not only the lymph nodes but other sites, organs or tissues, seem to represent a challenge not only for the lymphoma specialist but also for those physicians working with systems not primarily troubled by lymphomas frequently as lungs, gut, or skin.

Extranodal lymphomas seem to be occupying an important and interesting section of lymphoma medicine. They share with the lymph node lymphomas several common features in diagnosis, management, and care; however, they deserve some special attention as principles in their natural history may differ. Histopathology principles are also differentiated from the traditional lymphoma lymph node pathology. Similarly, prognosis and therapy are not the same. Accordingly, physicians should be aware of the current trends applied in investigating and also managing such lymphomas “of an unusual localization.”

Experience from all over the word on this special category of lymphomas is valuable. Every specialist involved in the topic has always a piece of valuable information to share with other scientists or clinicians. The benefits of taking advantages from such an experience cannot be ignored; the benefits for the patients who happen to be treated by the well-informed specialist cannot be underestimated.

To this effect, we are expecting to accumulate in this special issue of the journal the experience of colleagues from all over the world on extranodal lymphomas. The rarity of the cases makes valuable even contributions dealing with only one single case although it is hoped that review-like contributions are of major importance and interest as they are expected to describe the current state of the art. All aspects of extranodal lymphomas are encouraged, for example, epidemiology, histopathology/cytology, imaging (including illustrations), clinical-and-differential diagnosis, staging, and therapeutics. We will be pleased to welcome papers on nervous system, skin and mucosa associated lymphomas, and also lymphomas of unusual sites like pleural cavity and genitalia-urinary system. Long-term follow-up reports are also extremely encouraged as we are keen to see whether the long-term observations on other lymphoma cases are also shared by extranodal lymphomas.

Authors can submit their manuscripts through the Manuscript Tracking System at

Submission DeadlineFriday, 4 May 2018
Publication DateSeptember 2018

Papers are published upon acceptance, regardless of the Special Issue publication date.

Special Issue Editor in Chief

Guest Editors